Abstract
Recently, a novel intestinal bacterial metabolite of ginseng protopanaxadiol saponins, i.e., 20-O-(beta-D-glucopyranosyl)-20(S)-protopanaxadiol (IH-901), has been reported to induce apoptosis in a variety of cancer cells. Here we show a differential effect of IH-901 on several cell types. Exposure to IH-901 for 48 hours at a supposedly subapoptotic concentration of 40 mumol/L led to both apoptotic cell death and G1 arrest in Hep3B cells, but only resulted in G1 arrest in MDA-MB-231, Hs578T, and MKN28 cells. Additionally, the treatment of MDA-MB-231, but not of Hep3B, with IH-901 up-regulated cyclooxygenase-2 (COX-2) mRNA (2 hours) and protein (6 hours), and enhanced the production of prostaglandin E2. In MDA-MB-231 cells, IH-901 induced the sustained activation of extracellular signal-regulated kinase (ERK), whereas inhibition of mitogen-activated protein/ERK kinase blocked IH-901-mediated COX-2 induction and resulted in apoptosis, suggesting the involvement of an ERK-COX-2 pathway. Combined treatment with IH-901 and nonsteroidal anti-inflammatory drugs inhibited COX-2 enzyme and induced apoptosis in MDA-MB-231 and Hs578T cells. Adenovirus-mediated COX-2 small interfering RNAs also effectively inhibited COX-2 protein expression and enhanced IH-901-mediated apoptosis without inhibiting ERK 1/2 phosphorylation, thus providing direct evidence that COX-2 is an antiapoptotic molecule. Moreover, IH-901-mediated G1 arrest resulted from an increase in p27Kip1 mRNA and protein expression followed by a decrease in CDK2 kinase activity that was concurrent with the hypophosphorylation of Rb and p130. In conclusion, IH-901 induced both G1 arrest and apoptosis, and this apoptosis could be inhibited by COX-2 induction.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Apoptosis / drug effects*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
CDC2-CDC28 Kinases / metabolism
-
Carcinoma, Hepatocellular / drug therapy
-
Carcinoma, Hepatocellular / metabolism
-
Carcinoma, Hepatocellular / pathology
-
Carrier Proteins / genetics
-
Carrier Proteins / metabolism
-
Cyclin-Dependent Kinase 2
-
Cyclin-Dependent Kinase Inhibitor p27
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / pharmacology
-
Extracellular Signal-Regulated MAP Kinases / metabolism
-
G1 Phase / drug effects
-
Humans
-
Intracellular Signaling Peptides and Proteins / genetics
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / metabolism
-
Liver Neoplasms / pathology
-
Membrane Proteins
-
Phosphorylation / drug effects
-
Prostaglandin-Endoperoxide Synthases / chemistry
-
Prostaglandin-Endoperoxide Synthases / genetics
-
Prostaglandin-Endoperoxide Synthases / metabolism*
-
Proteins / metabolism
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
RNA, Small Interfering / pharmacology
-
Retinoblastoma Protein / metabolism
-
Retinoblastoma-Like Protein p130
-
Sapogenins / pharmacology*
-
Tumor Cells, Cultured
Substances
-
20-O-(beta-D-glucopyranosyl)-20(S)-protopanaxadiol
-
Anti-Inflammatory Agents, Non-Steroidal
-
CDKN1B protein, human
-
Carrier Proteins
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Intracellular Signaling Peptides and Proteins
-
Membrane Proteins
-
Proteins
-
RBL2 protein, human
-
RNA, Messenger
-
RNA, Small Interfering
-
Retinoblastoma Protein
-
Retinoblastoma-Like Protein p130
-
Sapogenins
-
Cyclin-Dependent Kinase Inhibitor p27
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
CDC2-CDC28 Kinases
-
CDK2 protein, human
-
Cyclin-Dependent Kinase 2
-
Extracellular Signal-Regulated MAP Kinases